RARE DISEASE
Adenocarcinoma of ovary
Adenocarcinoma of ovary
Adenocarcinoma of ovary
Synonyms: Ovarian adenocarcinoma
Synonyms: Ovarian adenocarcinoma
Synonyms: Ovarian adenocarcinoma
Drug discovery
1
drug
With orphan designation
Overview
Ovarian adenocarcinoma, the most common epithelial ovarian cancer, arises from Müllerian epithelium and includes high-grade serous (most prevalent), endometrioid, clear cell, and mucinous subtypes [1][5]. Typically diagnosed at advanced stages (III/IV) due to nonspecific symptoms, it demonstrates varying chemosensitivity – clear cell and mucinous subtypes show particular resistance to platinum-based regimens [1][4][7]. Prognosis remains poor with 46% 5-year survival overall, dropping below 30% in advanced disease [4][10].
Categories: rare gynecological and obstetric diseases, rare neoplastic diseases
Research Papers
2,467 drug discovery papers about Adenocarcinoma of ovary, with 2 first-in-class and 8 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
2,467 drug discovery papers about Adenocarcinoma of ovary, with 2 first-in-class and 8 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
2026-07-01 | Complete Remission of Erythrodermic Psoriasis After Bevacizumab Administration for Ovarian Serous Adenocarcinoma: A Case Report
Patients who have both erythrodermic psoriasis and advanced ovarian cancer are uncommon in clinical practice. This case study presents the case of a patient diagnosed with erythrodermic psoriasis for a duration exceeding 4 years. The patient was administered ixekizumab and adalimumab, but no remission was observed during the illness. The patient was diagnosed with metastatic ovarian serous adenocarcinoma involving multiple lymph nodes and liver in 2022. During her bevacizumab treatment, she experienced a complete remission of psoriasis without any other management for psoriasis.
2026-06-09 | Identification of new targets for immunotherapy of ovarian adenocarcinoma based on the immunopeptidome of tumor cells
BACKGROUND. Ovarian adenocarcinoma is characterized by a high mortality rate due to late diagnosis and the development of resistance to standard chemotherapy. Despite the introduction of targeted therapies, the risk of recurrence remains high, highlighting the need for new therapeutic approaches. In this view, immunotherapy is a promising approach, but requires the identification of specific tumor antigens. AIM. To identify tumor antigens in ovarian adenocarcinoma that are promising for immunotherapy. METHODS. Immunopeptidome from cell lines and postoperative material of patients with ovarian adenocarcinoma were isolated using immunoaffinity chromatography followed by liquid chromatography-mass spectrometry analysis. RESULTS. In this study, we tested an affinity chromatography-based immunopeptidome isolation protocol, comparing various detergents (CHAPS, NP-40, SOD, and Triton X-100) for cell lysis, and observed no statistically significant differences in the number of identified peptides. Using NP-40, 5 peptides belonging to the proteins of cancer/testis antigens (CTA) were identified in the immunopeptidomes of postoperative material from patients with ovarian adenocarcinoma, 3 of which, according to the human protein atlas, are indeed not expressed in normal ovarian tissues. CONCLUSION. Each of the four tested detergents provides identification of unique sets of peptides. Immunopeptidome analysis allows the identification of peptides ofCTA proteins, but a larger sample of postoperative material from patients with ovarian adenocarcinoma and experimental testing of the immunogenicity of the identified peptides are needed for further research.
2026-06-06 | Overexpression of scavenger receptor class B member 2 leads to different response of ovarian adenocarcinoma cells to chemotherapy.
Scavenger Receptor Class B Member 2 (SCARB2) is an integral lysosomal membrane protein essential for lysosomal integrity and autophagy regulation. The aim of this study was to investigate the functional impact of SCARB2 overexpression on chemotherapy response, reactive oxygen species (ROS) production and proteomic composition of human ovarian adenocarcinoma cells A2780. To induce SCARB2 overexpression, A2780 cells were transfected using a PiggyBac vector system. Two clones with the highest SCARB2 expression (L and V) were selected for further analyses. Differences in chemosensitivity were assessed using the MTS assay. Proteomic analysis was used to identify differentially expressed proteins and enriched pathways. We also performed flow cytometry to investigate changes in ROS production and lysosomal activity. Lysosomal distribution was assessed using LAMP1 immunofluorescence staining followed by confocal microscopy, and total cholesterol levels were determined using an enzymatic colorimetric assay. Both clones showed increased sensitivity to cisplatin compared to the control group. In contrast, clone V showed resistance to doxorubicin and no significant differences were observed for gemcitabine, except for a transient sensitizing effect when low concentrations used. Elevated ROS levels were detected in untreated clones, and after doxorubicin exposition. Proteomic analysis showed significant changes in lysosome-associated proteins, with consistent enrichment of the lysosomal pathway across all experimental comparisons. Immunofluorescence analysis of LAMP1 and LysoTracker staining demonstrated altered lysosomal distribution and activity in SCARB2-overexpressing clones. In addition, both SCARB2-overexpressing clones exhibited significantly reduced total cholesterol levels compared with control cells. This study broadens our understanding of SCARB2 in ovarian cancer. SCARB2 overexpression induces extensive lysosomal reprogramming in A2780 ovarian cancer cells and modulates chemotherapy response.
2026-07-01 | Complete Remission of Erythrodermic Psoriasis After Bevacizumab Administration for Ovarian Serous Adenocarcinoma: A Case Report
Patients who have both erythrodermic psoriasis and advanced ovarian cancer are uncommon in clinical practice. This case study presents the case of a patient diagnosed with erythrodermic psoriasis for a duration exceeding 4 years. The patient was administered ixekizumab and adalimumab, but no remission was observed during the illness. The patient was diagnosed with metastatic ovarian serous adenocarcinoma involving multiple lymph nodes and liver in 2022. During her bevacizumab treatment, she experienced a complete remission of psoriasis without any other management for psoriasis.
2026-06-09 | Identification of new targets for immunotherapy of ovarian adenocarcinoma based on the immunopeptidome of tumor cells
BACKGROUND. Ovarian adenocarcinoma is characterized by a high mortality rate due to late diagnosis and the development of resistance to standard chemotherapy. Despite the introduction of targeted therapies, the risk of recurrence remains high, highlighting the need for new therapeutic approaches. In this view, immunotherapy is a promising approach, but requires the identification of specific tumor antigens. AIM. To identify tumor antigens in ovarian adenocarcinoma that are promising for immunotherapy. METHODS. Immunopeptidome from cell lines and postoperative material of patients with ovarian adenocarcinoma were isolated using immunoaffinity chromatography followed by liquid chromatography-mass spectrometry analysis. RESULTS. In this study, we tested an affinity chromatography-based immunopeptidome isolation protocol, comparing various detergents (CHAPS, NP-40, SOD, and Triton X-100) for cell lysis, and observed no statistically significant differences in the number of identified peptides. Using NP-40, 5 peptides belonging to the proteins of cancer/testis antigens (CTA) were identified in the immunopeptidomes of postoperative material from patients with ovarian adenocarcinoma, 3 of which, according to the human protein atlas, are indeed not expressed in normal ovarian tissues. CONCLUSION. Each of the four tested detergents provides identification of unique sets of peptides. Immunopeptidome analysis allows the identification of peptides ofCTA proteins, but a larger sample of postoperative material from patients with ovarian adenocarcinoma and experimental testing of the immunogenicity of the identified peptides are needed for further research.
2026-06-06 | Overexpression of scavenger receptor class B member 2 leads to different response of ovarian adenocarcinoma cells to chemotherapy.
Scavenger Receptor Class B Member 2 (SCARB2) is an integral lysosomal membrane protein essential for lysosomal integrity and autophagy regulation. The aim of this study was to investigate the functional impact of SCARB2 overexpression on chemotherapy response, reactive oxygen species (ROS) production and proteomic composition of human ovarian adenocarcinoma cells A2780. To induce SCARB2 overexpression, A2780 cells were transfected using a PiggyBac vector system. Two clones with the highest SCARB2 expression (L and V) were selected for further analyses. Differences in chemosensitivity were assessed using the MTS assay. Proteomic analysis was used to identify differentially expressed proteins and enriched pathways. We also performed flow cytometry to investigate changes in ROS production and lysosomal activity. Lysosomal distribution was assessed using LAMP1 immunofluorescence staining followed by confocal microscopy, and total cholesterol levels were determined using an enzymatic colorimetric assay. Both clones showed increased sensitivity to cisplatin compared to the control group. In contrast, clone V showed resistance to doxorubicin and no significant differences were observed for gemcitabine, except for a transient sensitizing effect when low concentrations used. Elevated ROS levels were detected in untreated clones, and after doxorubicin exposition. Proteomic analysis showed significant changes in lysosome-associated proteins, with consistent enrichment of the lysosomal pathway across all experimental comparisons. Immunofluorescence analysis of LAMP1 and LysoTracker staining demonstrated altered lysosomal distribution and activity in SCARB2-overexpressing clones. In addition, both SCARB2-overexpressing clones exhibited significantly reduced total cholesterol levels compared with control cells. This study broadens our understanding of SCARB2 in ovarian cancer. SCARB2 overexpression induces extensive lysosomal reprogramming in A2780 ovarian cancer cells and modulates chemotherapy response.
Access all drug discovery articles and probability of success in trials forecasts:
Access all drug discovery articles and probability of success in trials forecasts:
Drug Discovery Landscape
1 orphan drug designation for Adenocarcinoma of ovary, including 1 approved therapy.
1 orphan drug designation for Adenocarcinoma of ovary, including 1 approved therapy.
Drug | Therapy type | Regulator | Orphan designation | Approval | Sponsor |
|---|---|---|---|---|---|
Altretamine [Hexalen] | small molecules | FDA | 1984-02-09 | 1990-12-26 | Medimmune Oncology, Inc. |
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI's forecasts to outperform average preclinical success rates. Whether you're expanding your R&D pipeline, evaluating a partnership, or simply have a question — we'd love to hear from you.